Bladder Cancer | Clinical

Experts Review Important Treatment Options in Urothelial Cancer

January 14, 2021

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, two Mayo Clinic experts, Alan H. Bryce, MD, and Roxana S. Dronca, MD, discuss treatment options for a 66-year-old woman with urothelial carcinoma.

Eganelisib/Nivolumab Shows Encouraging Efficacy in Advanced, Metastatic Urothelial Carcinoma

January 07, 2021

Eganelisib, an investigational PI3K-gamma inhibitor in combination with nivolumab, demonstrated promising efficacy compared with nivolumab alone as treatment of platinum-refractory, immunotherapy naïve patients with advanced metastatic urothelial cancer, according to updated findings from the phase 2 MARIO-275 clinical trial.

Frontline Maintenance Therapy for Urothelial Cancer Emerges

December 30, 2020

After decades of dormancy, the therapeutic landscape of locally advanced/metastatic urothelial cancer underwent a paradigm shift—with multiple regulatory approvals of immune checkpoint inhibitors as second-line treatment—leading to changes in guideline-recommended management of patients in this setting.

Novel IL-15 Superagonist Complex Induces Response in bacillus Calmette-Guérin NMIBC With CIS

December 22, 2020

In patients with bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancerwith high-risk carcinoma in situ disease, the combination of intravesical BCG and N-803 demonstrated efficacy with a tolerable safety profile, according to findings from the pivotal phase 2/3 QUILT 3.032 study.

Atezolizumab More Likely to Benefit Urothelial Cancer With Detectable ctDNA

December 12, 2020

Adjuvant atezolizumab in patients with high-risk muscle-invasive urothelial cancer with detectable circulating tumor DNA demonstrated more benefit compared with those with MIUC and undetectable ctDNA, according to data from the IMvigor010 trial.

Jelmyto Induces Durable Responses in Patients With Low-Grade Upper Tract UC

December 05, 2020

Treatment with mitomycin-containing reverse thermal gel, led to complete responses in over 50% of patients with low-grade upper tract urothelial carcinoma, which were maintained at 1 year, final results from the pivotal phase 3 OLYMPUS trial show.

Nadofaragene Firadenovec Demonstrates Continued Efficacy Across Subgroups in BCG-Unresponsive NMIBC

December 03, 2020

In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.